Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant

OBJECTIVES: To evaluate the efficacy and safety of regdanvimab, a neutralizing antibody, in patients with mild-to-moderate SARS-CoV-2 including against the Delta variant. METHODS: A single-center, retrospective, observational cohort study in adults with confirmed COVID-19. The primary end point was...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Young Rock, Oh, Yoon Ju, Kim, Jin Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822548/
https://www.ncbi.nlm.nih.gov/pubmed/36623794
http://dx.doi.org/10.1016/j.ijid.2022.12.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822548/
https://www.ncbi.nlm.nih.gov/pubmed/36623794
http://dx.doi.org/10.1016/j.ijid.2022.12.035

Ejemplares similares